1. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?

2. Program Introduction

3. Technologies Used to Produce Therapeutic mAbs

4. Molecular Structures of Biologic Drugs Used to Treat Psoriasis

5. Biologics: Consequences of ADAs

6. Consequences of ADAs

7. Biologics: Types of ADAs

8. Relationship of Developing ADAs to Type of mAb

9. Immunogenicity of IL-17a and IL-12/23 Antibodies Are Low vs Other mAbs

10. Ixekizumab TE-ADAs Reported in the Phase 3 UNCOVER Trials

11. Relevance of ADAs for Treatment Strategies With Human or Chimeric Antibodies

12. Concluding Remarks

13. Abbreviations